Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "pediatric ALL" Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

NCT05918822
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I

NCT00661453
View directory record Official record
Conditions
Spinal Muscular Atrophy Type I
Interventions
Valproic Acid and Levocarnitine
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Weeks to 12 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
6
States / cities
Baltimore, Maryland • Detroit, Michigan • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Jul 23, 2026, 10:19 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA)

NCT07197294
View directory record Official record
Conditions
Neurodevelopmental Disorder With or Without Variable Brain Abnormalities
Interventions
nL-MAPK8-001
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
5 Years to 5 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 23, 2026, 10:19 AM EDT
Not yet recruiting No phase listed Observational

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

NCT07221656
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 23, 2026, 10:19 AM EDT
Recruiting Not applicable Interventional

iMOVE: Virtual Reality PT Versus Traditional PT

NCT05876156
View directory record Official record
Conditions
Physical Health
Interventions
Virtual Reality Physical Therapy, Traditional Physical Therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Assessing Continuous Glucose Monitors in Healthy Children

NCT00069602
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitoring System (CGMS), GlucoWatch G2TM Biographer (GW2B)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
6
States / cities
Stanford, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

NCT00006462
View directory record Official record
Conditions
Leukemia
Interventions
gemcitabine hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
197
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Testing "SupporT for ADHD and Related Treatment" (START) for Families of Children With ADHD

NCT05796427
View directory record Official record
Conditions
ADHD
Interventions
SupporT for ADHD and Related Treatment
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Years to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 10:19 AM EDT
Recruiting Phase 2 Interventional

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

NCT06847269
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 23, 2026, 10:19 AM EDT
Not yet recruiting Not applicable Interventional

An Automated Virtual Reality Intervention to Enhance Firearm Safety Counseling in Pediatrics

NCT07265141
View directory record Official record
Conditions
Virtual Reality, Medical Education, Motivational Interviewing, Gun Violence Prevention, Artificial Intelligence (AI)
Interventions
An Automated Virtual Reality Intervention to Support Firearm Safety Counseling in Clinicians
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

NCT00003573
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
filgrastim, cisplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
94
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Jul 23, 2026, 10:19 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Hemoglobin SC Disease With Hydroxyurea

NCT02336373
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
hydroxyurea
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
5 Years to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

NCT01416441
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 18 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
36
States / cities
Dothan, Alabama • Little Rock, Arkansas • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Jul 23, 2026, 10:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Prospective Cohort Study of HIV and Zika in Infants and Pregnancy

NCT03263195
View directory record Official record
Conditions
HIV, Zika Virus, Pregnant Women
Interventions
Not listed
Lead sponsor
Westat
Other
Eligibility
15 Years and older · Female only
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
4
States / cities
Miami, Florida • The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Jul 23, 2026, 10:19 AM EDT
Withdrawn Not applicable Interventional

Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy

NCT01233479
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
systemic chemotherapy, laboratory biomarker analysis, therapeutic surgical procedure, radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
4 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Jul 23, 2026, 10:19 AM EDT
Recruiting Phase 1 Interventional

Venetoclax to Augment Epigenetic Modification and Chemotherapy

NCT05317403
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
Venetoclax, Azacitadine, Vorinostat, Cytarabine, Fludarabine, Filgrastim
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Resistance Training on Musculoskeletal Endocrine Interactions

NCT02040727
View directory record Official record
Conditions
Musculoskeletal and Metabolic Crosstalk
Interventions
Resistance Training, No Resistance Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
7 Years to 12 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jul 23, 2026, 10:19 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Wise Social Psychological Interventions to Improve Outcomes of Behavioral Weight Control in Children With Obesity

NCT04422951
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Wise interventions -- values self-affirmation and growth mindset -- plus usual care behavioral treatment, Education plus usual care behavioral treatment
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 16 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Meaning Making While Your Child is in Intensive Care

NCT05627531
View directory record Official record
Conditions
Narrative Medicine
Interventions
Narrative Medicine
Behavioral
Lead sponsor
Akron Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

d13C Added Sugar Intake Biomarker: Determining Validity in Children

NCT02455388
View directory record Official record
Conditions
Validation Studies
Interventions
High added sugar diet, Low added sugar diet
Dietary Supplement
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
6 Years to 18 Years
Enrollment
370 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

NCT00021541
View directory record Official record
Conditions
Neurofibroma, Plexiform, Neurofibromatosis Type I
Interventions
tipifarnib, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Results available

Octaplas Pediatric Plasma Replacement Trial

NCT02050841
View directory record Official record
Conditions
Liver Surgery, Liver Dysfunction, Coagulopathy, Cardiac Surgery
Interventions
octaplas
Biological
Lead sponsor
Octapharma
Industry
Eligibility
Up to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Jul 23, 2026, 10:19 AM EDT
Completed Not applicable Interventional

Sternal Wall Pressure in the Cath Lab

NCT01117883
View directory record Official record
Conditions
Perfusion Pressures, Central Venous Pressure, Cardiac Output, CPR, Cardiac Arrest
Interventions
Application of two different sternal weights
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 7 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Jul 23, 2026, 10:19 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria, Children
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 10:19 AM EDT